{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:12Z","timestamp":1787064612052,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101320","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:08:48Z","timestamp":1752584928000},"page":"101320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Current trends and advances in the management of acquired Hemophilia A"],"prefix":"10.1016","volume":"74","author":[{"given":"Emilie","family":"Zuner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"D\u00e9sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdi","family":"Rezigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Dargaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lienhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Nougier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101320_bb0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1756-0500-3-161","article-title":"Consensus recommendations for the diagnosis and treatment of acquired hemophilia A","volume":"3","author":"Collins","year":"2010","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.blre.2025.101320_bb0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/JBM.S284804","article-title":"Acquired Hemophilia A: current guidance and experience from clinical practice","volume":"13","author":"Pishko","year":"2022","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2025.101320_bb0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","article-title":"Acquired hemophilia A: a review of recent data and new therapeutic options","volume":"22","author":"Franchini","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101320_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1773-035X(12)71502-2","article-title":"Les anticorps anti-FVIII et anti-FIX","volume":"2012","author":"Lebreton","year":"2012","journal-title":"Revue Francophone Des Laboratoires"},{"key":"10.1016\/j.blre.2025.101320_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1532\/IJH97.05113","article-title":"Factor VIII structure and function","volume":"83","author":"Fay","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101320_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V58.1.1.1","article-title":"The factor VIII complex: structure and function","volume":"58","author":"Hoyer","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0040","doi-asserted-by":"crossref","first-page":"11601","DOI":"10.1016\/S0021-9258(19)78167-8","article-title":"A role for the C2 domain of factor VIII in binding to von Willebrand factor","volume":"269","author":"Saenko","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2025.101320_bb0045","doi-asserted-by":"crossref","first-page":"31000","DOI":"10.1074\/jbc.274.43.31000","article-title":"Role of factor VIII C2 domain in factor VIII binding to factor Xa","volume":"274","author":"Nogami","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2025.101320_bb0050","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/JBM.S342077","article-title":"Acquired Haemophilia A: a review of what we know","volume":"13","author":"Mingot-Castellano","year":"2022","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2025.101320_bb0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood.V75.2.378.378","article-title":"Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients","volume":"75","author":"Nilsson","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0060","first-page":"73","article-title":"Immunochemical characterization of factor VIII inhibitors","volume":"150","author":"Hoyer","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.blre.2025.101320_bb0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.1972.tb03467.x","article-title":"The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs","volume":"23","author":"Biggs","year":"1972","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/hae.15144","article-title":"Factor VIII antibodies demonstrate Type I or Type II kinetics in acquired Haemophilia A","volume":"31","author":"Kamel","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0950-3536(96)80067-9","article-title":"Acquired inhibitors","volume":"9","author":"Cohen","year":"1996","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0080","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V60.5.1103.1103","article-title":"Inactivation of factor VIII coagulant activity by two different types of human antibodies","volume":"60","author":"Gawryl","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/diagnostics13030420","article-title":"Acquired Hemophilia A: an update on the etiopathogenesis, diagnosis, and treatment","volume":"13","author":"Zanon","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.blre.2025.101320_bb0090","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/asheducation-2006.1.432","article-title":"Acquired factor VIII inhibitors: pathophysiology and treatment","author":"Ma","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2025.101320_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101320_bb0100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0105","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2025.101320_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02259.x","article-title":"Genetic markers in acquired haemophilia","volume":"16","author":"Oldenburg","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0120","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1160\/TH13-05-0363","article-title":"Acquired haemophilia A: a 2013 update","volume":"110","author":"Franchini","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0125","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.045","article-title":"Acquired Haemophilia A: an intriguing disease","volume":"12","author":"Mazzucconi","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2025.101320_bb0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0037-1613257","article-title":"Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients","volume":"88","author":"Reding","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0140","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0145","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101320_bb0150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215 non-hemophilic patients with inhibitors to Factor VIII","volume":"45","author":"Green","year":"1981","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0155","first-page":"57","article-title":"Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future","volume":"85","author":"Kessler","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101320_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/hae.13355","article-title":"Acquired haemophilia in cancer: a systematic and critical literature review","volume":"24","author":"Napolitano","year":"2018","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.blre.2025.101320_bb0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: Updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol."},{"issue":"2","key":"10.1016\/j.blre.2025.101320_bb0170","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/hae.14233","article-title":"Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review","volume":"27","author":"Dewarrat","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1365-2516.2001.00506.x","article-title":"Postpartum acquired haemophilia: clinical recognition and management","volume":"7","author":"Kashyap","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.revmed.2022.04.012","article-title":"H\u00e9mophilie acquise et grossesse\u202f: une approche forc\u00e9ment multidisciplinaire","volume":"43","author":"L\u00e9vesque","year":"2022","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.blre.2025.101320_bb0185","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/jth.15421","article-title":"The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination","volume":"19","author":"Cittone","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0190","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.1002\/ajh.25865","article-title":"The first case of acquired hemophilia A associated with SARS-CoV-2 infection","volume":"95","author":"Franchini","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101320_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/hematolrep14020015","article-title":"Severe COVID-19 infection management in a patient with mild Haemophilia\u2014a case report","volume":"14","author":"An\u017eej Doma","year":"2022","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2025.101320_bb0200","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0034-1390004","article-title":"Laboratory diagnosis of acquired Hemophilia A: limitations, consequences, and challenges","volume":"40","author":"Tiede","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2025.101320_bb0205","first-page":"245","article-title":"Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding","author":"Coppola","year":"2022","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2025.101320_bb0210","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V49.5.793.793","article-title":"Detection of factor VIII inhibitors with the partial thromboplastin time","volume":"49","author":"Lossing","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jcm14010013","article-title":"Laboratory assessment of factor VIII inhibitors: When is it required? A perspective informed by local practice","volume":"14","author":"Favaloro","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101320_bb0220","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101320_bb0225","series-title":"Haemostasis: Methods and Protocols","first-page":"321","article-title":"Nijmegen-Bethesda assay to measure factor VIII inhibitors","author":"Duncan","year":"2013"},{"key":"10.1016\/j.blre.2025.101320_bb0230","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0037-1615080","volume":"79","author":"Giles","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0240","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ejh.13490","article-title":"Emicizumab treatment: impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)","volume":"105","author":"Nougier","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13435","article-title":"Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels","volume":"24","author":"Boylan","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0250","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2516.2007.01450.x","article-title":"ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay","volume":"13","author":"Sahud","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0255","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ijlh.14109","article-title":"International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors","volume":"45","author":"Meijer","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.blre.2025.101320_bb0260","series-title":"Diagnosis of Hemophilia and other bleeding disorders: a laboratory manual","author":"Montalvao","year":"2025"},{"key":"10.1016\/j.blre.2025.101320_bb0265","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.jtha.2024.07.001","article-title":"Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU\/mL","volume":"22","author":"Verbruggen","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0270","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0275","series-title":"NOVOSEVEN 1 mg (50 KUI) pdre\/solv p sol inj","year":"2025"},{"key":"10.1016\/j.blre.2025.101320_bb0280","series-title":"FEIBA 50 U\/ml pdre\/solv p sol inj","year":"2025"},{"key":"10.1016\/j.blre.2025.101320_bb0285","series-title":"OBIZUR 500 U pdre\/solv p sol inj","year":"2025"},{"key":"10.1016\/j.blre.2025.101320_bb0290","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101320_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0300","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0305","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1111\/hae.14335","article-title":"Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A","volume":"27","author":"Chen","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0310","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2516.2008.01927.x","article-title":"The use of combination FEIBA and rFVIIa bypassing therapy, with TEG profiling, in uncontrollable bleeding associated with acquired haemophilia A","volume":"15","author":"Dunkley","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0315","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/hae.13139","article-title":"Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia","volume":"23","author":"Hay","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0320","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hae.13033","article-title":"Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data","volume":"23","author":"Amano","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0325","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ejh.13592","article-title":"Principles of care for acquired hemophilia","volume":"106","author":"Dolan","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0330","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101320_bb0335","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0340","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.thromres.2015.10.032","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study","volume":"136","author":"Zanon","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2025.101320_bb0345","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MBC.0000000000000716","article-title":"A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre","volume":"29","author":"\u00c1roksz\u00e1ll\u00e1si","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2025.101320_bb0350","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","article-title":"Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity","volume":"2","author":"Aledort","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0360","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.15175","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) in acquired haemophilia A: a large multicentre Italian study \u2013 the FAIR Registry","volume":"184","author":"Zanon","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0365","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2516.2012.02803.x","article-title":"Porcine factor VIII","volume":"18","author":"Giangrande","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0370","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13040","article-title":"Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients","volume":"23","author":"Tarantino","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0380","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1111\/hae.13038","article-title":"Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy","volume":"22","author":"Martin","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0385","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1111\/hae.13046","article-title":"Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy","volume":"22","author":"Stemberger","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0390","first-page":"312","article-title":"Susoctocog-alfa (Obizur\u00ae) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience","volume":"18","author":"Zanon","year":"2020","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2025.101320_bb0395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/hematolrep15010003","article-title":"Acquired Hemophilia A treated with recombinant porcine Factor VIII: case report and literature review on its efficacy","volume":"15","author":"Borro","year":"2023","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2025.101320_bb0400","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.14618","article-title":"Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 Study","volume":"18","author":"T\u00fcrkantoz","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0405","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241260332","article-title":"Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS","volume":"15","author":"Miesbach","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101320_bb0410","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.3390\/jcm12144590","article-title":"Surgery and prophylaxis with Susoctocog-Alfa in acquired Hemophilia: case series and literature review","volume":"12","author":"Sella","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101320_bb0415","series-title":"HEMLIBRA 150 mg\/ml sol inj","year":"2025"},{"key":"10.1016\/j.blre.2025.101320_bb0420","article-title":"Emicizumab for the treatment of acquired Hemophilia A: consensus recommendations from the GTH-AHA Working Group","author":"Pfrepper","year":"2023","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.blre.2025.101320_bb0425","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0430","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101320_bb0435","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0440","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0445","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101320_bb0450","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.jtha.2024.06.010","article-title":"Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A","volume":"22","author":"Hart","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0455","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/a-2384-3585","article-title":"Final analysis results from the AGEHA Study: Emicizumab Prophylaxis for acquired Hemophilia A with or without immunosuppressive therapy","volume":"125","author":"Shima","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0460","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2516.2012.02748.x","article-title":"Combined treatment with APCC (FEIBA\u00ae) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience","volume":"18","author":"Holmstr\u00f6m","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0470","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: a randomized trial in 108 patients","volume":"237","author":"L\u00e9vesque","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2025.101320_bb0475","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-0038-1649664","article-title":"A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies","volume":"70","author":"Green","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101320_bb0480","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1179\/1607845414Y.0000000152","article-title":"Low-dose rituximab in the treatment of acquired haemophilia","volume":"19","author":"Yao","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101320_bb0485","article-title":"Rituximab for eradicating inhibitors in people with acquired haemophilia A","volume":"8","author":"Remmington","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2025.101320_bb0490","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101320_bb0495","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/MBC.0b013e32832ca388","article-title":"The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis","volume":"20","author":"Bitting","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2025.101320_bb0500","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/hae.13685","article-title":"Relapse pattern and long-term outcomes in subjects with acquired haemophilia A","volume":"25","author":"Mizrahi","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101320_bb0505","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/hematology.2020000116","article-title":"Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases","volume":"2020","author":"Malpica","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2025.101320_bb0510","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101320_bb0515","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.rce.2015.08.003","volume":"215","author":"Gonz\u00e1lez-Mac\u00edas","year":"2015","journal-title":"Rev Clin Esp (Barc)"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:33:22Z","timestamp":1766079202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":103,"alternative-id":["S0268960X25000657"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101320","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current trends and advances in the management of acquired Hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101320"}}